Article

How to choose the best visual field testing strategy for neuro-ophthalmic patients

Every patient should undergo at least screening confrontation visual field testing.

Table 1 by Johnson and Keltner summarizes the seven main types of visual field loss.

In my opinion, every patient should undergo at least screening confrontation visual field testing but formal perimetry is especially recommended for patients with visual loss. Choosing the right strategy for the neuro-ophthalmic patient can be challenging and there are a number of modalities to choose from (Table 2).


The Amsler grid is a quick and useful assessment of the central 10° field. Amsler testing can detect small central or paracentral scotomas or define metamorphopsia especially in macular disorders (e.g., macular hole, epiretinal or subretinal membrane). The tangent screen is another rapid and particularly useful test and I find it particularly useful for a non-organic "tunnel" visual field that does not expand at 1-and2-m test distance.

Although becoming increasingly unavailable, the Goldmann manual perimeter is still a very powerful diagnostic tool. The strength and weakness of the test is the dependence upon an experienced field technician.

Summary The choice of visual field strategy is dependent upon both patient and visual field-related factors. The majority of neuro-ophthalmic conditions (e.g., optic neuropathies, bitemporal or homonymous hemianopsias) can be evaluated adequately by automated central testing (e.g., 24-2 or 30-2 Humphrey). Newer thresholding algorithms (e.g., Humphrey SITA) have improved the testing time and reliability.

Despite the widespread adoption of automated perimetry, there is still a role for Goldmann perimetry in patients who are unable to perform a reliable automated test, for visual field defects outside of the central 24° or 30°, and for more detailed information on the shape of a particular visual field defect.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
© 2025 MJH Life Sciences

All rights reserved.